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Metastatic disease is the primary cause of mortality among patients with osteogenic sarcoma (OGS). In this study, we aimed to
identify the relationship of COPS3 gene expression to metastasis. Immunohistochemical staining for COPS3 was performed on 65
OGS samples (37 without and 28 with metastatic disease); 18.9% (7/37) of specimens from patients with no metastasis and 57.1%
(16/28) of specimens from patients with metastasis showed intense staining of COPS3. Comparison of COPS3 expression between a
poorly metastatic osteosarcoma cell line (SAOS-2) and highly metastatic osteosarcoma cell line (HOS) showed stronger expression
of COPS3 in HOS cells. Inhibiting COPS3 function by siRNA resulted in reduced proliferation and migration of HOS cells.
Inhibition of COPS3 gene downregulated expression of the MAPK signaling pathway, which has an important role in metastasis of
OGS. Our results suggested that overexpression of the COPS3 gene might have important roles in metastasis of osteosarcoma cells.
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Introduction
Osteogenic sarcoma (OGS) is the most common primary
malignant tumor of the bone. It is characterized by a local
aggressiveness, with a tendency to metastasize to the lung
and bone in children and young adolescents.
1,2 Approxi-
mately 10–20% of patients have metastases at the time of
diagnosis.
3 Without adjuvant chemotherapy, more than
half of the patients treated by surgery alone develop
metastases within 6 months and more than 80% develop
recurrent disease within 2 years of diagnosis.
4 The use of
multiagent chemotherapy, in addition to surgery, has
dramatically increased long-term survival for patients
with OGS, with a disease-free 5-year survival reaching
65–70% for patients with localized disease.
5,6 However,
patients who develop metastatic disease still have an
extremely dismal prognosis. A 5-year survival for patients
with metastatic OGS remains as low as 20%, even with
the introduction of chemotherapy three decades ago.
Metastasis remains the primary cause of poor survival of
patients with OGS.
Metastasis development is a complex and multistage
process involving local invasion, access to the circulation,
seeding and eventual proliferation within a favorable
distant target organ.
7,8 Several genes, including WT1,
CXCR4, TEM7 and PTHR1,
9–12 have been recently
reported to be associated with metastasis of OGS.
Khanna et al.
13 reported that the membrane-cytoskeleton
linkage protein Ezrin is necessary for OGS metastasis and
that there is a significant association between high Ezrin
expression and poor outcome in pediatric OGS patients.
Despite these recent advances, the process of metastasis
still remains incompletely characterized at both the
molecular and biochemical levels.
Amplification of several genes that map to a region of
chromosome 17p11.2, including COPS3, was observed in
high-grade osteosarcoma. Comparative genomic hybridi-
zation studies revealed amplification of this region in
13–29% of high-grade osteosarcomas,
14,15 suggesting the
presence of an oncogene (or oncogenes) whose activation
may contribute to osteosarcoma tumorigenesis. In studies
with small sample sizes, COPS3 had been found to be
amplified in 32–63% of osteosarcoma specimens and was
also shown to be overexpressed and potentially involved
in osteosarcoma tumorigenesis.
16,17 Recently, it has been
shown that COPS3 amplification strongly correlates with
large tumor size (P¼0.0009).
18 In the clinical setting,
tumor volume is reportedly associated with lung metas-
tasis in patients with osteosarcoma.
19 We hypothesize that
COPS3 could regulate OGS growth and metastasis and
might correlate with poor patient outcome.
In this report, we evaluated immunohistochemically the
expression pattern of COPS3 in OGS specimens and
correlated these findings with the occurrence of metas-
tasis. We then compared COPS3 expression between
OGS cell lines with different metastasis potentials and
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www.nature.com/cgtdeveloped an siRNA-based approach to inhibit COPS3
expression. Finally, we evaluated the roles of COPS3 in
migration of the osteosarcoma cell line.
Materials and methods
Patient specimens
A study of 65 patients with OGS, undergoing surgery at
the Musculo-Skeletal Tumor Center of Peking University
People’s Hospital, Beijing, China, during the period
1997–2008, was performed. The median age at diagnosis
was 19 years (range 5–79). Primary histological examina-
tion was performed at the Department of Pathology,
Peking University People’s Hospital. Histologic tumor
slides were reevaluated by two pathologists. All patients
were free of metastatic disease at the time of diagnosis.
Treatment protocols of these patients were in the same
fashion. In all cases, Institutional Review Board-ap-
proved protocols were followed to collect specimens,
and the study had the approval from the Hospital
Research Ethics Committee.
Cell culture and reagents
OGS-derived cell lines (HOS and SAOS-2) were obtained
from American Type Cell Collection (Manassas, VA)
and cultured in 1640 medium containing 10% fetal
bovine serum, 1% antibiotics–antimycotics (Invitrogen,
Carlsbad, CA) in a 5% CO2-humidified atmosphere
at 371C. Anti-COPS3 and anti-actin were purchased
from Santa Cruz Biotechnology, Santa Cruz, CA. Anti-
MEK/pMEK, anti-ERK/pERK and anti-AKT/pAKT
were purchased from Biworld Antibody Company,
St Louis, MO.
Western blotting
The procedure for western blotting analysis is briefly
described below. After inhibiting COPS3 function by
siRNA, total protein was extracted from the indicated
cells with lysis buffer (0.15 M NaCl, 5mM EDTA, pH 8,
10mM Tris-Cl, pH 7.4, 1% Triton-X100). Protein
concentrations were determined by Bradford assay. Equal
amounts of protein (20mg) were electrophoresed by 10%
SDS-PAGE and transferred onto a nylon membrane
(Millipore Corporation, Billerica, MA), and then the
membrane was probed with the appropriate antibodies.
RNAi-mediated gene knockdown
A 19-nucleotide target sequence derived from human
COPS3 mRNA (NCBI Reference Sequence: NM_003653,
272–290bp) was designed by siRNA Wizard software of
the Invitrogen Corporation. The siRNA duplexes for
COPS3 were synthesized by Gene-Chem (Shanghai,
China). The sequences of the siRNA targeting COPS3
were the following: sense strand 50-GCACATTCGATA
TGCAACA-30 and antisense strand 50-TGTTGCATA
TCGAATGTGC-30. A scrambled sequence-control siR-
NA was also designed: sense strand 50-TTCTCC
GAACGTGTCACGT-30 and antisense strand 50-ACGT
GACACGTTCGGAGAA-30. Basic Local Alignment
Search Tool searches of the human genome database
were carried out to ensure that the sequences would not
target other gene transcripts. Plasmids expressing siRNA
were under the control of the human U6 promoter in the
pGCsi-U6/Neo/GFP plasmid (Gene-Chem).
Proliferation assay
Proliferation was investigated using a 3-4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
assay. Cells were seeded in 96-well plate in 200ml media
containing 10% dialyzed fetal bovine serum at a density
of 6000 cell, in the presence or absence of COPS3 or HOS
cells, respectively. On the following day 1, 2, 3, 4 and 5, to
evaluate the cell number, 20ml MTT solution (5mgml
 1
in medium) was added to the cultured cells, which were
further incubated for 4h at 371C. After removing the
remaining medium, 150ml dimethyl sulfoxide was added
to each well to solubilize the precipitate. The resulting
color intensity, which is proportional to the number of
viable cells, was measured by a microplate reader (versa
max, Molecular Devices, Sunnyvale, CA) at 490nm.
Migration assay
Migration assays were performed using a 24-well invasion
chamber system (BD Biosciences, Franklin Lakes, NJ).
Cells were seeded in the upper chamber at
2 10
5cellsml
 1 in 0.1ml serum-free 1640 media. Media
supplemented with 10% fetal bovine serum was placed in
the bottom well in a volume of 0.8ml (used as a
chemoattractant). After overnight incubation at 371Ci n
an atmosphere containing 5% CO2, migrated cells on the
lower surface were stained with 0.2% hematoxylin and
counted under a light microscope. All experiments were
repeated at least once.
Immunohistochemistry
Paraffin-embedded human osteosarcoma tissues were
fixed in freshly prepared 10% neutral buffered formalin,
embedded in paraffin wax, and cut into 5mm sections.
After baking at 601C overnight, sections were dewaxed
and rehydrated. Endogenous peroxidase activity was
blocked by 3% hydrogen peroxide for 10min at room
temperature. After being blocked with 5% skim milk,
sections were incubated with the COPS3 antibody
(5mgml
 1)a t41C overnight, followed by the incubation
with the second antibody from EnVisionTM kit (Dako
Cytomation, Glastrup, Denmark) for 30min at room
temperature. Reaction product was visualized with
diaminobenzidine (Sigma, St Louis, MO) for 5min at
room temperature. Sections were counterstained with
hematoxylin. Purified IgG from normal mouse serum was
used as negative control. Evaluation of COPS3 immunor-
eactivity was carried out independently by two experi-
enced pathologists, without any knowledge of the clinical
data. The analysis was assessed according to both the
percentage of positive cells and the intensity of the
cytoplasmic staining in 10 randomly chosen microscopic
fields. The staining intensity was classified as following:
no staining or staining observed in o10% of tumor cells
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tumor cells was scored as 1þ; and a moderate or strong
complete staining observed in X10% of tumor cells was
scored as 2þ or 3þ, respectively. The frequency of
expression was stratified into two groups—low staining
(0, 1þ immunopositivity) and high staining (2þ and 3þ
immunopositivity).
Statistical analysis
Data are shown as means±s.d. Student’s t-test and
w
2-test were used for statistical analyses. Po0.05 values
were considered significant.
Results
OGS patients with strong COPS3 expression were more
likely to metastasize
The expression of COPS3 in 65 OGS samples was
analyzed immunohistochemically. Overall, 43.1% (28/65)
of patients with OGS developed metastasis within 3–5
years. There was a statistically significant relationship
between strong COPS3 staining and patients who devel-
oped metastatic disease, compared with those who didn’t
(Po0.01). Overall, 18.9% (7/37) of patients without
metastasis and 57.1% (16/28) of patients with metastasis
showed strong staining for COPS3 (Table 1).
Cells derived from highly metastatic OGS cell lines
express high levels of COPS3
We compared COPS3 expression in osteosarcoma cell
lines with different metastatic potential. HOS and
SAOS-2 cell lines were subjected to analysis by western
blotting. A representative result from these experiments,
presented in Figure 1, shows that the expression of
COPS3 in SAOS-2 is about 30% compared with the
expression of COPS3 in HOS.
siRNA directed against COPS3 inhibit expression of
COPS3 in OGS cells
The above data from cell line and tumor tissue analyses
imply a potentially important role for COPS3 in OGS. To
further explore any specific role of COPS3 in OGS, the
first step is to develop a cellular model that sustains
forced inhibition of COPS3 expression. On the basis of
this idea, we employed siRNA to silence the expression
of COPS3 in HOS cell lines, which showed a high level of
expression of COPS3. We employed an siRNA oligos,
which can efficiently knockdown COPS3 expression in
HOS cell line. The expression of COPS3 in COPS3-silenced
and non-silenced OGS cell line were confirmed at the
protein levels by western blot (Figure 2), confirming that
the siRNA inhibited about 77% of the expression of
COPS3 in HOS cell lines.
Table 1 Relationship between COPS3 immunostaining and tumor









Figure 1 COPS3 expression in OGS cell lines with different
metastatic potential. COPS3 expression is little in SAOS-2, but a
high expression level in HOS.
Figure 2 COPS3 knockdown osteosarcoma model was estab-
lished in vitro. COPS3 expression levels were measured in normal
HOS, empty vector-only HOS and COPS3-knockdown HOS cells by
western blots. A significantly lower level of COPS3 protein were
detected in COPS3-knockdown HOS cells compared with the
positive control and negative control.PC: normal HOS cell (postive
control); NC: empty vector-only HOS cell (negative control); KD:
COPS3-knockdown HOS cell **indicates Po0.01 as compared with
PC and NC, respectively.
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proliferation and migration of HOS cells in vitro
Having established the conditions for silencing COPS3
expression in HOS cells, we used this cell line to assess the
role of COPS3 in proliferation and migration, which are
necessary for successful cancer metastasis. We found that
silencing of COPS3 had a profound negative impact on
proliferation and migration of HOS cells (B50% reduc-
tion) (Figures 3 and 4).
Inhibiting COPS3 expression by siRNA inhibits
expression of the MAPK signaling pathway
After silencing COPS3 expression in HOS cell line, we
examined the activity of the mitogen-activated protein
kinases (MAPK) signaling pathway. Total and phos-
phorylated ERK1/2 and MEK were assessed. As shown
in Figure 5, the total ERK1/2 and MEK levels in HOS
cells have not changed, but the phosphorylation of
ERK1/2 and MEK was decreased by about 70% and
58%, respectively, after silencing of COPS3. We also
examined the AKT pathway and found that neither total
AKT protein levels nor phosphorylation of AKT was
affected by RNAi (Figure 6).
Discussion
OGS is the most common pediatric primary bone tumor
characterized by local aggressiveness and a tendency to
metastasize to the lung and bone. Unfortunately, there are
few clinical predictors of outcome for osteosarcoma.
20–22
Patients who present with metastases have the worst
prognosis and are rarely curable.
23,24 The mechanisms by
which initiation and propagation of the metastatic process
of OGS occur are largely unknown.
25 Therefore, prog-
nostication and choice of therapy is largely guided by
tumor grade. Clearly, identification of molecular factors
that govern metastasis and/or other clinical parameter
will have a significant impact on the management of
patients with OGS.
Amplification of COPS3, which encodes one subunit
of a highly conserved complex, the COP9 signalosome,
has been reported in high-grade osteosarcoma.
26,27 It has
been reported that COPS3 has an important role in the
ubiquitination and, ultimately, in the degradation of the
tumor suppressor p53. The amplification and overexpres-
sion of COPS3 in osteosarcoma may represent another
route to p53 protein degradation equivalent to mutational
inactivation of p53.
28–30 Henriksen
31 reported that in
osteosarcoma with COPS3 amplification, no cases had
MDM2 amplification or p53 mutation, suggesting that
COPS3 is an alternative mechanism for p53 inactivation
in these tumors. The frequent amplification of COPS3
Figure 3 Proliferation assay. Our data showed that COPS3
knockdown HOS cell line was followed by a significantly reduced
ability of the cells to grow, compared with PC and NC, respectively.
*Po0.05 and **Po0.01 as compared with PC and NC, respectively.
Figure 4 Migration assay. Our data showed that COPS3 knockdown HOS cell line was followed by a significantly reduced ability of the cells to
migrate, compared with PC and NC, respectively. *Po0.05 and **Po 0.01 as compared with PC and NC, respectively.
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progression of osteogenic sarcoma, including regulation
of the cell cycle, proliferation, differentiation, apoptosis
and signal transduction.
We recently utilized quantitative real-time polymerase
chain reaction to detect copy number changes for COPS3
in 155 osteosarcomas from a prospective collection of
tumors, with corresponding clinical data. Results showed
that osteosarcomas with COPS3 amplification and sub-
sequent overexpression may have a growth advantage
with a higher proliferative capacity, leading to increased
tumor size. COPS3 amplification was significantly corre-
lated with poor patient outcome (Po0.042). In the
clinical setting, we have found that tumor volume is
associated with the occurrence of lung metastasis.
Munajat
19 reviewed 70 patients with histopathologically
confirmed primary osteosarcoma in the extremities, who
had magnetic resonance imaging and computed tomo-
graphy of the thorax less than one month before
treatment, with reference to the official report of tumor
dimensions and lung metastasis by radiologists. This
study found that 33 (47%) had evidence of lung
metastasis. Tumor volume was directly associated with
occurrence of lung metastasis (P¼0.048). The proportion
having lung metastasis when the primary tumor volume
exceeded 371cm
3 was 69%, compared with 34% of those
with smaller tumors.
16 In the present study, we studied 65
osteosarcomas with corresponding clinical data and
analyzed the association of COPS3 expression and
metastasis. Strong COPS3 expression was detected in 23
of 65 tumors (35.3%), similar to results of previous
studies.
16,17 Overall, 18.9% (7/37) of patients without
metastatic disease expressed strong staining for COPS3;
however, 57.1% (16/28) of patients with metastasis
disease showed strong staining for COPS3. We speculate
that COPS3, acting as an oncogene, could regulate OGS
growth and metastasis and thus correlate with poor
patient outcome. On the basis of such a premise, we
further study the role of COPS3 in the OGS cell line. We
first identified COPS3 gene overexpression in highly
metastatic OGS cells, compared with poorly metastatic
tumor cells. We then inhibited COPS3 function by siRNA
to analyze the phenotypic effects. We found that
inhibition of COPS3 expression by siRNA reduced
proliferation and migration of HOS by unknown
mechanisms. To further evaluate this, we investigated
the activity of MAPKs, which belong to serine-threonine
kinases family. MAPK signaling has an important role in
several features of cancer progression, including angio-
genesis, proliferation, apoptosis and metastasis.
32 MAPK
pathway has been demonstrated to be overexpressed in
most OGS and has been hypothesized to contribute to the
Figure 5 Expression of the MAPK signaling pathways between HOS empty vector-only HOS cell and COPS3-knockdown HOS cell. Equal
amounts of total protein were resolved on SDS-PAGE gels. Western blot analysis was performed using specific antibodies against the indicated
proteins. Blots were reprobed for actin to normalize each lane for protein content.
Figure 6 Changes in the expression of proteins AKT and P-AKT between HOS empty vector-only HOS cells and COPS3-knockdown HOS
cells.
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COPS3 may cross talk with the MAPK pathway in the
development of OGS metastasis. As COPS3 is a
nucleoprotein, increased expression of COPS3 may first
activate the expression of MAPK pathway, leading to
increased metastatic potential. Our present data show that
silencing COPS3 in HOS cell inactivates the MAPK/ERK
pathway by reducing the levels of phosphorylated
ERK1/2 and MEK. Evidently, this concept will require
evaluation through an appropriate animal model.
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